Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin

The use of an alpha emitter for radioimmunotherapy has potential advantages compared with beta emitters. When administered systemically optimal targeting of intact antibodies requires >24 h, therefore limiting the use of short-lived alpha emitters. This study investigated the biodistribution of b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2004-05, Vol.10 (9), p.3137
Hauptverfasser:	Yao, Zhengsheng, Zhang, Meili, Garmestani, Kayhan, Axworthy, Donald B, Mallett, Robert W, Fritzberg, Alan R, Theodore, Lou J, Plascjak, Paul S, Eckelman, William C, Waldmann, Thomas A, Pastan, Ira, Paik, Chang H, Brechbiel, Martin W, Carrasquillo, Jorge A
Format:	Artikel
Sprache:	eng
Schlagworte:	Alpha Particles - therapeutic use Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - pharmacokinetics Biotin - analogs & derivatives Biotin - chemistry Biotin - pharmacokinetics Biotin - therapeutic use Bismuth - chemistry Bismuth - pharmacokinetics Bone Marrow - pathology Bone Marrow - radiation effects Cell Line, Tumor Dose-Response Relationship, Radiation Female Humans Kidney - pathology Kidney - radiation effects Mice Mice, Inbred BALB C Mice, Nude Organometallic Compounds - chemistry Organometallic Compounds - pharmacokinetics Organometallic Compounds - therapeutic use Radioimmunotherapy - adverse effects Radioimmunotherapy - methods Radioisotopes Spleen - pathology Spleen - radiation effects Survival Analysis Time Factors Tissue Distribution Treatment Outcome Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!